Does dexamethasone suppress the Mazzotti reaction in patients with onchocerciasis?

Autor(en): Stingl, P. / Pierce, P.F. / Connor, D.H.
Objekttyp: Article
Zeitschrift: Acta Tropica
Band (Jahr): 45 (1988)
Heft 1

Persistenter Link: https://doi.org/10.5169/seals-314060

Nutzungsbedingungen

Haftungsausschluss
Alle Angaben erfolgen ohne Gewähr für Vollständigkeit oder Richtigkeit. Es wird keine Haftung übernommen für Schäden durch die Verwendung von Informationen aus diesem Online-Angebot oder durch das Fehlen von Informationen. Dies gilt auch für Inhalte Dritter, die über dieses Angebot zugänglich sind.
Does dexamethasone suppress the Mazzotti reaction in patients with onchocerciasis?

P. Stingl1, 2, P. F. Pierce3, 4, D. H. Connor4, 5, D. W. Gibson4, T. Straessle1, M. A. Ross4, 6, J. L. Ribas4

Summary

The Mazzotti reaction is a frequent complication in patients with onchocerciasis being treated with diethylcarbamazine (DEC); and more severe manifestations of this reaction may be unacceptable in many patients. It has recently been demonstrated that prednisone modifies the severity of this reaction and reduces the microfilaricidal activity of DEC. A clinical trial was performed at the National Leprosy Training Center in Wau, Sudan, to evaluate the clinical and histologic effect of the use of corticosteroids in patients receiving DEC. Administration of a low dose of dexamethasone (3 mg/day), begun after onset of the Mazzotti reaction, modifies the progression of the Mazzotti reaction without interfering with the microfilaricidal efficacy of DEC. Pretreatment with low-dose dexamethasone – prior to beginning DEC therapy – prevents the development of the Mazzotti reaction and greatly reduces the microfilaricidal activity. Administration of diphenhydramine, after onset of the Mazzotti reaction, has no effect on the course and intensity of the Mazzotti reaction nor on microfilaricidal activity. We recommend that low-dose corticosteroids be administered in conjunction with DEC – after onset of the Mazzotti reaction – and that they be tapered rapidly.

Key words: onchocerciasis; Mazzotti reaction; diethylcarbamazine; dexamethasone; diphenhydramine.

Correspondence: Dr. Dean W. Gibson, Department of Infectious and Parasitic Disease Pathology, Armed Forces Institute of Pathology, Washington, D.C. 20306-6000, USA
Introduction

Diethylcarbamazine (DEC) has been the primary drug therapy for the treatment of onchocerciasis for nearly four decades since its introduction (Mazzotti, 1948). The principal adverse effect has been termed the Mazzotti reaction and is characterized by one or more of the following: pruritus, skin rash, eye complications, glandular reactions, cardiovascular symptoms, musculo-skeletal pain, headache, or vertigo (Mazzotti, 1948; Satti and Kirk, 1957; Fuglsang and Anderson, 1974; Bryceson et al., 1977). Corticosteroids have been reported to suppress the Mazzotti reaction (Fuglsang and Anderson, 1974; Anderson and Fuglsang, 1978; Awadzi et al., 1982; Titanji et al., 1983); under the regimens in those studies, however, the microfilaricidal efficacy of the DEC was greatly reduced.

We report here studies of the effects of administering dexamethasone – after onset of the Mazzotti reaction vs. before DEC therapy is begun – on the subsequent course of the Mazzotti reaction and also on the microfilaricidal efficacy of the DEC therapy in patients with onchocerciasis. Both clinical and histopathologic changes are reported for the various regimens. The mechanism by which DEC causes the Mazzotti reaction is re-examined in view of these findings.

Patients in this study lived in villages in Bahr El Ghazal Province of southern Sudan, where numerous earlier studies have shown onchocerciasis to be hyperendemic (Cruickshank, 1936; Satti and Kirk, 1957; Kirk et al., 1959; Haseeb et al., 1962; Abdalla, 1974; Enarson, 1977; El Sheikh, 1985; Ghalib et al., 1985; Kaneene et al., 1985; Satti, 1985; Williams et al., 1985a, b; Stingl, 1986). Patients in the present study were among nearly 200 onchocerciasis patients under various treatment regimens at the National Leprosy Training Centre (NLTC) in Wau, Sudan; results have been previously presented for a subgroup of onchocerciasis patients with leprosy who received oral DEC (without steroids) and regular dapsone therapy for leprosy (Stingl and Stingl, 1982), and for a subgroup that received a topical DEC “patch test” (Stingl et al., 1984).

Materials and Methods

Sixteen patients were admitted to the NLTC for treatment with DEC. There were nine men and seven women, ranging in age from 18 to 38 years (Table 1). All patients lived in hyperendemic villages of Bahr El Ghazal province, and all were found to have onchocerciasis on clinical and parasitological examination. Three of the 16 patients were being followed for leprosy.

Skin snips were taken from the outer canthus, scalpula, iliac crest, and calf with a Walser-type corneoscleral punch. The snips were weighed on a torsion balance and incubated in physiologic saline. Microfilariae that had emerged into the incubation medium were counted at 24 h, and the tissue parasitic burden (microfilariae per mg of skin; mf/mg) was calculated. The aggregate microfilarial density (AMD) was determined by adding densities at the four sites (Awadzi et al., 1980).

Biopsy specimens of skin were taken through areas of clinical change, fixed in formalin, and sent to the Armed Forces Institute of Pathology, Washington, DC, for histopathologic study. The specimens were embedded in paraffin and cut at section thicknesses of 6 μm. Slides were stained with
hematoxylin and eosin, Giemsa, and Russell-Movat procedures, as previously described (Connor et al., 1970, 1985; Gibson et al., 1976, 1980).

All sixteen patients received an equivalent total dosage of 3.225 g DEC over 14 days, according to the following regimen:

<table>
<thead>
<tr>
<th>Day No.</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6 through 14 [entire 14-day course]</th>
</tr>
</thead>
<tbody>
<tr>
<td>mg DEC</td>
<td>25</td>
<td>50</td>
<td>100</td>
<td>150</td>
<td>200</td>
<td>300 (&lt;9 days) [3225 mg DEC, total dosage]</td>
</tr>
</tbody>
</table>

These patients were treated randomly with one of three regimens (groups A, B, and C), to modify their response to DEC:

Group A: Three patients (Nos. 1–3) received dexamethasone, 1.5 mg BID, for three days prior to receiving the initial oral dose of 25 mg DEC; and dexamethasone was continued for an additional 3 days, while DEC was increased in a stepwise manner (regimen above). A skin biopsy specimen was taken from one patient in group A: patient 3 at day 5.

Group B: Seven patients (Nos. 4–10) receiving DEC had dexamethasone initiated after the onset of symptoms consistent with a Mazzotti reaction; dexamethasone dosage was begun at 1.5 mg BID and was then tapered over 7 days. No biopsy specimens were taken from patients in group B.

Group C: Six patients (Nos. 11–16) were treated with diphenhydramine, 50 mg TID, after the Mazzotti reaction began during DEC therapy. Biopsy specimens were taken from two patients in group C: patient 11 at day 7 and patient 14 at days 12 and 18.

Results

The three patients pretreated with dexamethasone (group A) had very mild adverse responses to DEC: two experienced mild pruritus and the third was asymptomatic. The seven patients receiving dexamethasone after onset of the Mazzotti reaction (group B) experienced relief of symptoms within one day of beginning dexamethasone and by day 3 no further Mazzotti reaction was evident. Of the six patients treated with diphenhydramine after onset of the Mazzotti reaction (group C), pruritus improved in only one; no effect was observed in the other five patients.

The pretreatment and posttreatment aggregate microfilarial densities are shown in Table 1. For group A, no significant reduction in AMD was seen in patients 1 and 2 at day 5; and a 48% reduction occurred in patient 3 at day 10. Patients in groups B and C had 69% to 100% (92% average) and 100% reductions of AMDs, respectively.

Skin biopsy specimens from selected patients (one from group A; two from group C) demonstrated similar results to the AMDs. A specimen from patient 3 of group A (day 5) demonstrated many microfilariae, mostly in the upper dermis, but none were degenerating or centered within foci of inflammation. The characteristic features of untreated onchocercal dermatitis were present: hyperpigmentation of keratin and one pigmented hyperkeratotic focus (tombstone), sclerotic dermal papillae, pigmentary incontinence, and dilated lymphatics (Fig. 1). Histiocytes, plasma cells, and lymphocytes surrounded
Table 1. Effects of dexamethasone and diphenhydramine on aggregate microfilarial density (AMD) and on the Mazzotti reaction to equivalent DEC dosage

<table>
<thead>
<tr>
<th>Patient No.</th>
<th>Age (yrs), sex</th>
<th>Pretreatment AMD&lt;sup&gt;b&lt;/sup&gt;</th>
<th>Posttreatment AMD&lt;sup&gt;b&lt;/sup&gt; (therapy day)</th>
<th>% Change in AMD&lt;sup&gt;b&lt;/sup&gt;</th>
<th>Mazzotti reaction</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>25, ♂</td>
<td>1548</td>
<td>1510 (5)</td>
<td>−2.4%</td>
<td>mild itching</td>
</tr>
<tr>
<td>2&lt;sup&gt;c&lt;/sup&gt;</td>
<td>26, ♀</td>
<td>39</td>
<td>42 (5)</td>
<td>+7.7%</td>
<td>asymptomatic</td>
</tr>
<tr>
<td>3</td>
<td>30, ♂</td>
<td>108</td>
<td>56 (10)&lt;sup&gt;d&lt;/sup&gt;</td>
<td>−48.2%</td>
<td>mild itching</td>
</tr>
</tbody>
</table>

**Group A – pretreatment with dexamethasone**

<p>| | | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td>38, ♂</td>
<td>227</td>
<td>70 (21)</td>
<td>−69.3%</td>
<td>relieved</td>
</tr>
<tr>
<td>5</td>
<td>18, ♀</td>
<td>320</td>
<td>40 (11)</td>
<td>−87.5%</td>
<td>relieved</td>
</tr>
<tr>
<td>6</td>
<td>29, ♂</td>
<td>717</td>
<td>50 (15)</td>
<td>−93.0%</td>
<td>partial relief</td>
</tr>
<tr>
<td>7</td>
<td>37, ♂</td>
<td>106</td>
<td>0 (17)</td>
<td>−100.0%</td>
<td>relieved</td>
</tr>
<tr>
<td>8</td>
<td>19, ♀</td>
<td>61</td>
<td>0 (16)</td>
<td>−100.0%</td>
<td>partial relief</td>
</tr>
<tr>
<td>9</td>
<td>20, ♂</td>
<td>427</td>
<td>26 (10)</td>
<td>−93.9%</td>
<td>relieved</td>
</tr>
<tr>
<td>10&lt;sup&gt;e&lt;/sup&gt;</td>
<td>19, ♂</td>
<td>257</td>
<td>0 (17)</td>
<td>−100.0%</td>
<td>itch persisted</td>
</tr>
</tbody>
</table>

**Group B – dexamethasone with Mazzotti reaction**

<p>| | | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>11</td>
<td>27, ♀</td>
<td>7</td>
<td>0 (10)&lt;sup&gt;f&lt;/sup&gt;</td>
<td>−100.0%</td>
<td>no change</td>
</tr>
<tr>
<td>12</td>
<td>18, ♀</td>
<td>61</td>
<td>0 (16)</td>
<td>−100.0%</td>
<td>malaise improved</td>
</tr>
<tr>
<td>13</td>
<td>18, ♂</td>
<td>18</td>
<td>0 (12)</td>
<td>−100.0%</td>
<td>no change</td>
</tr>
<tr>
<td>14</td>
<td>33, ♀</td>
<td>193</td>
<td>0 (27)&lt;sup&gt;f&lt;/sup&gt;</td>
<td>−100.0%</td>
<td>no change</td>
</tr>
<tr>
<td>15</td>
<td>20, ♂</td>
<td>380</td>
<td>0 (25)</td>
<td>−100.0%</td>
<td>no change</td>
</tr>
<tr>
<td>16&lt;sup&gt;c&lt;/sup&gt;</td>
<td>20, ♀</td>
<td>12</td>
<td>0 (9)</td>
<td>−100.0%</td>
<td>no change</td>
</tr>
</tbody>
</table>

**Group C – diphenhydramine with Mazzotti reaction**

<p>| | | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>11</td>
<td>27, ♀</td>
<td>7</td>
<td>0 (10)&lt;sup&gt;f&lt;/sup&gt;</td>
<td>−100.0%</td>
<td>no change</td>
</tr>
<tr>
<td>12</td>
<td>18, ♀</td>
<td>61</td>
<td>0 (16)</td>
<td>−100.0%</td>
<td>malaise improved</td>
</tr>
<tr>
<td>13</td>
<td>18, ♂</td>
<td>18</td>
<td>0 (12)</td>
<td>−100.0%</td>
<td>no change</td>
</tr>
<tr>
<td>14</td>
<td>33, ♀</td>
<td>193</td>
<td>0 (27)&lt;sup&gt;f&lt;/sup&gt;</td>
<td>−100.0%</td>
<td>no change</td>
</tr>
<tr>
<td>15</td>
<td>20, ♂</td>
<td>380</td>
<td>0 (25)</td>
<td>−100.0%</td>
<td>no change</td>
</tr>
<tr>
<td>16&lt;sup&gt;c&lt;/sup&gt;</td>
<td>20, ♀</td>
<td>12</td>
<td>0 (9)</td>
<td>−100.0%</td>
<td>no change</td>
</tr>
</tbody>
</table>

<sup>a</sup> All patients received 3.225 g DEC over 14 days (regimen in Materials and Methods).

<sup>b</sup> AMD is the sum of microfilarial densities (mf/mg) in skin snips from four sites: outer canthus, scapula, iliac crest, and calf (Awadzi et al., 1980).

<sup>c</sup> Leprosy patients, under regular dapsone therapy, with clinical classifications: patient 2, lepromatous leprosy; patient 10, borderline lepromatous leprosy; patient 16, borderline tuberculoid leprosy.

<sup>d</sup> Biopsy specimen taken from skin of calf on day 5 of DEC therapy (cf. Fig. 1).

<sup>e</sup> Biopsy specimen taken from skin of iliac crest on day 7 of DEC therapy (cf. Fig. 2).

<sup>f</sup> Biopsy specimens taken from skin of thigh on days 12 and 18 of DEC therapy (cf. Figs. 3 and 4).

neurovascular channels and intact microfilariae in all layers of dermis. Some of these microfilariae had increased eosinophilia, but apart from the latter there was no histologic evidence of a Mazzotti reaction. An early specimen from patient 11 of group C (day 7) showed hyperpigmented keratin; acanthosis; many “tombstones” characteristic of post-DEC changes; and histiocytes, lymphocytes, and plasma cells surrounded blood vessels (Fig. 2). Also present in the dermis were melanophores and a few intact microfilariae. A later specimen from patient 14 of group C (day 12) was similar but showed degenerating microfilariae surrounded by degranulating eosinophils (Figs. 3 and 4). In a still
Fig. 1. Skin from the calf of patient 3 (group A – pretreated 3 days with dexamethasone) on day 5 after beginning treatment with DEC. In the upper dermis there is a fragment of a microfilaria (arrow) without degeneration, surrounding eosinophils or other post-DEC reaction (contrast with Figs. 3 and 4). Thus, pretreatment with steroids has inhibited the Mazzotti reaction. There are increased numbers of fibroblasts in the dermal collagen; some sclerosis of dermal papillae; a dilated lymphatic in the upper dermis; some acanthosis; and a parakeratotic nest in the keratin – all characteristic features of untreated onchocercal dermatitis. Hematoxylin and eosin, 250x (AFIP Neg. 85–9960).

Fig. 2. Skin from the iliac crest of patient 11 (group C – diphenhydramine with Mazzotti reaction) on day 7 after beginning treatment with DEC. There is a small (early) intraepidermal abscess (arrow) – a common feature after treatment with DEC. No microfilariae are in the abscess. Hematoxylin and eosin, 250x (AFIP Neg. 85–9961).

later specimen from patient 14 (day 18), the microfilariae had cleared, but the dermatitis persisted.

There was one patient with leprosy in each group (patients 2, 10, and 16 in groups A, B, and C, respectively). Patient 10 experienced itching longer than other patients in group B but had a 100% reduction in AMD. Patients 2 and 16 responded similarly clinically and by reduction in AMD to other members of their respective groups.
Figs. 3 and 4 (different magnifications of same field – box in Fig. 3). Skin from the thigh of patient 14 (group C – diphenhydramine with Mazzotti reaction) on day 12 after beginning treatment with DEC. There is an eosinophilic abscess in the upper dermis in which degranulating eosinophils surround a degenerating microfilaria – seen in tangential and cross sections (arrows in Fig. 4). In contrast to pretreatment with dexamethasone (cf. Fig. 1), diphenhydramine has not suppressed these characteristic features of the Mazzotti reaction. Just below the basal layer is an intact microfilaria (arrow in Fig. 3). Hematoxylin and eosin, 250x and 1000x (AFIP Negs. 85–9963 and 85–9964).

Discussion

This study provides histologic support to previous clinical studies that demonstrated modification of the Mazzotti reaction by corticosteroids. The use of low-dose dexamethasone, 3 mg/day, in combination with standard doses of
diethylcarbamazine resulted in limiting the Mazzotti reaction to mild pruritus and the elimination of hypotension, glandular reactions, and eye itching and tearing. Steroidal use, following onset of the Mazzotti reaction (group B), did not alter treatment effectiveness, since the average reduction of microfilariae was 91% compared to 100% reduction in group C (no corticosteroids). The dosage of steroids used in this study was quite low: 3 mg/day of dexamethasone, which is equivalent in steroid activity to 15 mg prednisone. Previous studies have used 60 mg prednisone (Awadzi et al., 1982), and this higher dosage may have caused the reduction of microfilariae by 79% of pretreatment counts.

The three patients with leprosy included in this study did not respond differently from the other patients. The Mazzotti reaction was suppressed, and the outcome of treatment was similar to other patients with onchocerciasis.

Pretreatment with dexamethasone prior to DEC (group A) did not result in reductions in AMD similar to those for groups B and C discussed above. Furthermore, the skin biopsy performed on patient 3 demonstrated many intact microfilariae with little of the inflammatory response typical of patients treated with DEC. These findings indicate that pretreatment with even low-dose corticosteroids may result in inadequate treatment of onchocercal dermatitis. Pretreatment with prednisone (at higher dosage) was used in the above-cited study by Awadzi et al. (1982). The ability of the microfilariae to survive despite DEC treatment in patients premedicated with dexamethasone provides further insight into the mechanism of action of DEC. Previous studies have demonstrated the ineffectiveness of DEC in vitro against microfilariae of *Onchocerca volvulus* (Hawking, 1950; Hawking et al., 1950). This study supports the finding that it is the eosinophil that damages the microfilaria and the effect of DEC is indirect (Kephart et al., 1984). Corticosteroid inhibition of eosinophil function is well-recognized. Gibson et al. (1976) first observed that after treatment with DEC microfilariae in the dermis were intensely eosinophilic and surrounded by eosinophils, indicating degeneration of these microfilariae. Pretreatment with corticosteroids eliminated the inflammation surrounding the microfilariae and reduced microfilarial density (AMD) by less than 50% (Table 1, group A). Corticosteroids that were begun with the onset of the Mazzotti reaction (group B) lessened symptoms dramatically and did not adversely affect the outcome.

We have demonstrated that the timing of the administration of corticosteroids is an important determinant of treatment outcome in patients with onchocercal dermatitis. Pretreatment with corticosteroids reduces DEC effectiveness to an unacceptable level. We recommend that low-dose corticosteroids be administered after the onset of the Mazzotti reaction and that they be tapered rapidly. Based on our findings, we cannot recommend pretreatment with corticosteroids. Our results must be considered preliminary in view of the small number of patients investigated and the variable time interval between initiation of the treatment and pathologic assessment.
New drug therapy for onchocerciasis is being developed (Aziz et al., 1982; Taylor, 1984; Awadzi et al., 1985; Green et al., 1985); however, diethylcarbamazine remains the principle treatment. Modification of the Mazzotti reaction will permit less toxic therapy until better drugs are widely available.

Acknowledgments

This work was supported in part by the German Leprosy Relief Association (DAHW), and in part by the World Health Organization (WHO), Geneva. The histopathologic specimens are filed in the WHO Collaborating Centre for the Histopathology of Filarial Diseases in Man, at the AFIP. Mrs. Maria Stingl performed all the laboratory work in the Sudan. Ms. Dale Slavin helped organize the data on the patients in the early stages of the study at AFIP. The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the DAHW, WHO, the Department of the Army or the Department of Defense, or the institutions with which the authors are affiliated.


